Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Neuromolecular Med. 2013 Nov 23;16(2):292–307. doi: 10.1007/s12017-013-8277-3

Figure 1.

Figure 1

AS101 treatment delays the onset and attenuates the progression of EAE in mice. C57BL/6 mice were immunized with MOG35-55 mixed with CFA (5 sham mice, 15 PBS-treated EAE mice and 15 AS101-treated EAE mice). Pertussis toxin was injected on days 0 and 2. AS101 (1 mg/kg) was administered once daily beginning on day 0 (MOG immunization). (A) Values for clinical scores measured daily. The values for AS101 versus PBS in EAE mice were significant on days 12 – 21 (**p<0.01). (B) Body weights were measured once per week. (C) Rotarod test results. The values for AS101 versus PBS in EAE mice were significant at the 2 and 3 week time points (*p<0.05; **p<0.01). (D) Representative examples of spinal cord sections from the indicated groups stained with Luxol Fast Blue (14 days post-immunization). (E) Results of measurements of lesion areas determined from Luxol Fast Blue-stained spinal cord sections of mice in the indicated groups at the indicated post-immunization time points. **p<0.01 compared to the corresponding value for the AS101-treated group.